SCHEMBL21241871

SCHEMBL21241871

CS(=O)(=O)c1cccc(C(=O)NCC(=O)Nc2nc(-c3ccc4c(c3)OCCO4)cs2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 12/20 0.61
▸ NPC1 O15118 11/20 0.61
▸ MAPT P10636 11/20 0.61
▸ SMN1; SMN2 Q16637 10/20 0.61
▸ LMNA P02545 7/20 0.61
▸ ALDH1A1 P00352 6/20 0.61
▸ NFKB1 P19838 3/20 0.61
▸ NFKB2 Q00653 3/20 0.61
▸ RELA Q04206 3/20 0.61
▸ KMT2A Q03164 9/20 0.59
▸ MEN1 O00255 8/20 0.59
▸ GAA P10253 1/20 0.59
▸ CLK1 P49759 2/20 0.58
▸ KDM4E B2RXH2 5/20 0.56
▸ TSHR P16473 2/20 0.53
▸ HSD17B10 Q99714 1/20 0.53
▸ POLB P06746 2/20 0.52
▸ HTT P42858 1/20 0.52
▸ KDM4A O75164 1/20 0.51
▸ KDM4B O94953 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21224261 0.91 RAB9A (0.58) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL21225263 0.85 KDM4A (0.62) MAPTSMN1; SMN2LMNAALDH1A1KMT2A
SCHEMBL21225354 0.84 KDM4A (0.59) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL22971499 0.83 KDM4A (0.57) MAPTSMN1; SMN2LMNAALDH1A1CLK1
SCHEMBL21241913 0.82 KDM4A (0.49) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL21241927 0.82 RAB9A (0.66) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL22306207 0.81 RAB9A (0.65) RAB9ANPC1MAPTSMN1; SMN2LMNA
SCHEMBL22971656 0.81 KDM4A (0.52) MAPTSMN1; SMN2LMNAALDH1A1GAA
SCHEMBL25108373 0.80 KDM4A (0.56) MAPTSMN1; SMN2LMNAALDH1A1KMT2A
SCHEMBL21241908 0.80 KDM4A (0.56) RAB9AMAPTSMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138480-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-04 — — US disclosed
US-20210038611-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2021-02-11 — — US disclosed
WO-2019152437-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2019-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230138480-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885NPC1 138/4885MAPT 2074/4885
US-20210038611-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB RAB9A 572/4885NPC1 138/4885MAPT 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback